CPHI - China Pharma Holdings Inc Stock Price, Fair Value and News

0.33USD0.00 (0.00%)Market Closed

Market Summary

USD0.330.00

Market Closed

0.00%

CPHI Stock Price

View Fullscreen

CPHI RSI Chart

CPHI Valuation

Market Cap

5.2M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

0.82

EV/EBITDA

-9.67

Price/Free Cashflow

28.56

CPHI Price/Sales (Trailing)

CPHI Profitability

Operating Margin

-11.67%

EBT Margin

-55.42%

Return on Equity

-42.92%

Return on Assets

-21.98%

Free Cashflow Yield

3.5%

CPHI Fundamentals

CPHI Revenue

Revenue (TTM)

6.4M

Rev. Growth (Yr)

-30.12%

Rev. Growth (Qtr)

-36.28%

CPHI Earnings

Earnings (TTM)

-3.6M

Earnings Growth (Yr)

-100.83%

Earnings Growth (Qtr)

22.42%

Breaking Down CPHI Revenue

Last 7 days

3.1%

Last 30 days

-2.9%

Last 90 days

230.0%

Trailing 12 Months

6.5%

How does CPHI drawdown profile look like?

CPHI Financial Health

Current Ratio

0.89

CPHI Investor Care

Shares Dilution (1Y)

62.98%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.4M	0	0	0
2023	8.5M	7.9M	7.8M	7.0M
2022	8.9M	8.1M	8.1M	8.1M
2021	11.5M	10.1M	9.7M	9.6M
2020	9.8M	11.0M	11.0M	10.9M
2019	11.6M	11.0M	11.1M	10.9M
2018	13.5M	13.8M	12.9M	12.3M
2017	15.4M	14.7M	13.9M	13.2M
2016	18.3M	17.6M	16.8M	16.1M
2015	20.7M	20.3M	19.2M	20.4M
2014	31.7M	29.8M	27.2M	22.1M
2013	46.7M	40.1M	36.0M	32.8M
2012	79.1M	74.1M	65.3M	54.5M
2011	76.1M	77.8M	79.5M	81.2M
2010	0	0	0	74.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of China Pharma Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 29, 2023	li zhilin	acquired	1,925,990	0.14	13,757,100	ceo & interim cfo
Sep 09, 2021	li zhilin	acquired	1,179,200	0.67	1,760,000	ceo & interim cfo
Dec 23, 2020	li zhilin	acquired	-	-	2,000,000	ceo and interim cfo

Which funds bought or sold CPHI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	new	-	34,993	34,993	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-20,112	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-33,642	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	5,300	5,300	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-2,000	-	-%
May 13, 2024	UBS Group AG	new	-	2,721	2,721	-%
May 13, 2024	UBS Group AG	sold off	-100	-4,150	-	-%
May 10, 2024	JPMORGAN CHASE & CO	sold off	-100	-7,916	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling CPHI?

Are funds buying CPHI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CPHI

No. of Funds

Unveiling China Pharma Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 26, 2024	liu tao (chengdu)	27.3%	1.5e+07	SC 13G
Jan 12, 2024	streeterville capital llc	9.99%	3,291,872	SC 13G/A
Mar 09, 2023	deng ke	19.4%	15,522,293	SC 13G
Dec 05, 2022	streeterville capital llc	9.99%	5,159,088	SC 13G/A
Sep 27, 2022	streeterville capital llc	9.99%	4,994,517	SC 13G

Recent SEC filings of China Pharma Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 29, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report
Feb 14, 2024	EFFECT	EFFECT
Feb 14, 2024	CORRESP	CORRESP
Feb 08, 2024	8-K	Current Report

Peers (Alternatives to China Pharma Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

China Pharma Holdings Inc News

Latest updates

China Pharma Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-36.3%	1,369,839	2,149,686	1,803,461	1,097,862	1,960,290	2,921,000	1,965,931	1,613,156	1,604,005	2,889,368	1,978,627	2,415,559	2,358,371	2,931,104	2,400,667	3,770,723	1,763,955	3,048,411	2,376,844	2,569,408	2,929,273
Cost Of Revenue	-25.5%	1,659,863	2,228,844	2,036,651	1,244,523	1,782,366	2,878,318	2,103,687	1,842,537	1,773,466	2,587,432	2,275,023	2,344,559	2,085,641	2,369,631	2,353,471	2,620,925	1,569,516	2,759,064	2,004,085	2,405,860	2,272,743
Gross Profit	-266.4%	-290,024	-79,158	-233,190	-146,661	177,924	42,682	-137,756	-229,381	-169,461	301,936	-296,396	71,000	272,730	561,473	47,196	1,149,798	194,439	289,347	372,759	163,548	656,530
Operating Expenses	-43.4%	626,028	1,105,333	480,352	309,647	575,403	1,211,694	550,898	550,212	742,257	950,626	466,008	823,948	969,198	1,662,977	999,690	1,074,813	793,719	18,964,820	1,017,963	916,516	990,738
S&GA Expenses	-58.3%	108,187	259,552	206,524	169,820	144,432	364,397	259,376	266,451	179,561	536,902	134,292	445,478	378,335	507,567	654,090	727,642	326,095	754,943	613,110	505,866	478,691
R&D Expenses	-78.7%	31,451	147,552	45,773	23,747	23,008	27,999	88,747	15,063	54,049	54,048	21,374	53,456	190,086	261,473	37,628	30,044	48,819	53,995	39,716	66,008	69,918
EBITDA Margin	-5988.6%	-0.07	0.00	0.00	0.00	-0.04	-0.10	-0.03	0.00	0.00	0.02	-0.02	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-16.1%	42,155	50,252	66,240	137,663	79,445	96,175	103,976	110,041	124,427	333,441	64,903	72,392	71,265	107,945	61,067	63,144	62,003	70,094	67,590	97,254	86,780
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	22.4%	-955,892	-1,232,213	-777,600	-593,029	-475,976	-1,264,184	-790,773	-888,394	-1,029,490	-980,719	-826,669	-824,761	-767,327	-1,209,037	-1,009,896	13,053	-660,897	-18,745,256	-700,954	-838,103	-417,731
EBT Margin	-26.2%	-0.55	-0.44	-0.40	-0.39	-0.40	-0.49	-0.46	-0.46	-0.41	-0.35	-0.37	-	-	-	-	-	-	-	-	-	-
Net Income	22.4%	-955,892	-1,232,213	-777,600	-593,029	-475,976	-1,264,184	-790,773	-888,394	-1,029,490	-980,719	-826,669	-824,761	-767,327	-1,209,037	-1,009,896	13,053	-660,897	-18,745,256	-700,954	-838,103	-417,731
Net Income Margin	-26.2%	-0.55	-0.44	-0.40	-0.39	-0.40	-0.49	-0.46	-0.46	-0.41	-0.35	-0.37	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-2521.3%	-585,158	-22,323	1,034,554	-189,167	-1,440,946	611,862	-33,427	-509,114	-880,830	-205,168	-866,823	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.7%	16.00	16.00	15.00	16.00	17.00	18.00	16.00	18.00	21.00	23.00	18.00	20.00	20.00	21.00	21.00	23.00	22.00	22.00	40.00	43.00	45.00
Current Assets	-14.6%	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	8.00	9.00	4.00	5.00	5.00	5.00	5.00	7.00	6.00	6.00	6.00	8.00	8.00
Cash Equivalents	-41.1%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	4.00	5.00	0.00	2.00	1.00	1.00	0.00	2.00	0.00	1.00	1.00	2.00	1.00
Inventory	-1.4%	4.00	4.00	4.00	4.00	4.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00
Net PPE	-9.2%	6.00	7.00	8.00	8.00	9.00	10.00	10.00	11.00	13.00	13.00	14.00	14.00	15.00	16.00	16.00	16.00	16.00	16.00	17.00	18.00	19.00
Liabilities	-12.4%	8.00	9.00	9.00	11.00	13.00	13.00	13.00	14.00	16.00	17.00	11.00	13.00	13.00	13.00	13.00	15.00	14.00	13.00	13.00	14.00	15.00
Current Liabilities	-16.0%	6.00	7.00	7.00	11.00	12.00	13.00	13.00	8.00	10.00	11.00	10.00	12.00	11.00	11.00	12.00	11.00	11.00	10.00	10.00	9.00	9.00
Shareholder's Equity	11.2%	8.00	7.00	6.00	4.00	5.00	4.00	3.00	4.00	5.00	6.00	7.00	7.00	7.00	8.00	8.00	8.00	8.00	9.00	27.00	29.00	31.00
Retained Earnings	-2.4%	-40.25	-39.29	-38.10	-37.28	-36.69	-36.21	-34.95	-34.16	-33.27	-32.24	-31.26	-30.43	-29.61	-28.84	-27.63	-26.62	-26.63	-25.97	-7.23	-6.53	-5.69
Additional Paid-In Capital	5.1%	37.00	35.00	33.00	30.00	29.00	29.00	26.00	26.00	26.00	26.00	26.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00
Accumulated Depreciation	1.9%	31.00	30.00	-	-	-	28.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	39.4%	15.00	11.00	29.00	8.00	8.00	1.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-
Float	-	-	-	-	4.00	-	-	-	11.00	-	-	-	17.00	-	-	-	16.00	-	-	-	8.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-2521.3%	-585	-22.32	1,007	-216	-1,468	585	219	-333	-879	-198	-450	676	-276	335	-224	91.00	-244	-22.10	480	387	-236
Cashflow From Investing	100.0%	-	-4.53	-67.45	5.00	56.00	27.00	-252	-175	-1.39	-7.06	-415	-	-	233	-259	-492	-347	-50.26	-12.20	328*	-73.87
Cashflow From Financing	-77.4%	7.00	30.00	-476	934*	518	-672	28.00	-850	-275	4,620	-425	548	-145	-10.08	-1,233	1,975	-106	-4.99	-1,345	-110	-267

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CPHI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 1,369,839	$ 1,960,290
Cost of revenue	1,659,863	1,782,366
Gross profit (loss)	(290,024)	177,924
Operating expenses:
Selling expenses	108,187	144,432
General and administrative expenses	488,456	417,999
Research and development expenses	31,451	23,008
Reversal of allowance for doubtful accounts	(2,066)	(10,036)
Total operating expenses	626,028	575,403
Loss from operations	(916,052)	(397,479)
Other income (expense):
Interest income	2,315	948
Interest expense	(42,155)	(79,445)
Net other expense	(39,840)	(78,497)
Loss before income taxes	(955,892)	(475,976)
Income tax expense
Net loss	(955,892)	(475,976)
Other comprehensive income (loss) - foreign currency translation adjustment	(21,575)	205,322
Comprehensive loss	$ (977,467)	$ (270,654)
Loss per share:
Basic (in Dollars per share)	$ (0.07)	$ (0.29)
Weighted average shares outstanding (in Shares)	13,133,224	1,615,757

CPHI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Current Assets:
Cash and cash equivalents	$ 838,881	$ 1,423,838
Banker’s acceptances		65,915
Trade accounts receivable, less allowance for doubtful accounts of $13,759,993 and $13,786,074, respectively	358,765	504,448
Other receivables, less allowance for doubtful accounts of $27,083 and $27,017, respectively	32,220	157,944
Advances to suppliers	11,339	2,013
Inventories	3,679,065	3,732,517
Prepaid expenses	203,999	110,258
Total Current Assets	5,124,269	5,996,933
Property, plant and equipment, net	6,450,692	7,100,425
Right-of-use assets	97,006	116,610
Intangible assets, net	4,518,482	3,255,232
TOTAL ASSETS	16,190,449	16,469,200
Current Liabilities:
Trade accounts payable	647,828	966,420
Accrued expenses	114,636	298,829
Other payables	2,117,222	2,282,692
Advances from customers	112,357	90,507
Lease liabilities	78,284	77,727
Current portion of lines of credit	1,028,894	1,030,680
Convertible, redeemable note payable, net of issue discount	490,000	940,000
Total Current Liabilities	5,728,016	6,820,664
Non-current Liabilities:
Lines of credit, net of current portion	1,409,443	1,411,891
Deferred tax liability	740,828	742,114
Lease liabilities	20,008	39,910
Total Liabilities	7,898,295	9,014,579
Commitments and Contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 14,816,865 shares and 10,625,788 shares issued and outstanding, respectively	14,816	10,625
Additional paid-in capital	37,093,065	35,282,256
Accumulated deficit	(40,246,206)	(39,290,314)
Accumulated other comprehensive income	11,430,479	11,452,054
Total Stockholders’ Equity	8,292,154	7,454,621
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	16,190,449	16,469,200
Related Party
Current Liabilities:
Borrowings from related parties	$ 1,138,795	$ 1,133,809

About China Pharma Holdings Inc

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

CEO	Ms. Zhilin Li
WEBSITE	chinapharmaholdings.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	234

China Pharma Holdings Inc Frequently Asked Questions

What is the ticker symbol for China Pharma Holdings Inc? What does CPHI stand for in stocks?

CPHI is the stock ticker symbol of China Pharma Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of China Pharma Holdings Inc (CPHI)?

As of Fri May 17 2024, market cap of China Pharma Holdings Inc is 5.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CPHI stock?

You can check CPHI's fair value in chart for subscribers.

What is the fair value of CPHI stock?

You can check CPHI's fair value in chart for subscribers. The fair value of China Pharma Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of China Pharma Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CPHI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is China Pharma Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether CPHI is over valued or under valued. Whether China Pharma Holdings Inc is cheap or expensive depends on the assumptions which impact China Pharma Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPHI.

What is China Pharma Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CPHI's PE ratio (Price to Earnings) is -1.47 and Price to Sales (PS) ratio is 0.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPHI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on China Pharma Holdings Inc's stock?

In the past 10 years, China Pharma Holdings Inc has provided -0.22 (multiply by 100 for percentage) rate of return.